Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2002-07-16
2009-10-20
Richter, Johann R (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S675000
Reexamination Certificate
active
07605179
ABSTRACT:
Provided are napthoquinone-type compounds which can be used to modulate the aggregation of protein (e.g. tau) associated with neurodegenerative disease (e.g. Alzheimer's disease). Structure-function characteristics for oxidised and reduced napthoquinone-type compounds, such as menadione-related compounds, are disclosed. The invention further provides methods of treatment or prophylaxis of neurodegenerative diseases and/or clinical dementias based on the compounds.
REFERENCES:
patent: 4897388 (1990-01-01), Malluche
patent: 5763479 (1998-06-01), Chayen et al.
patent: 6953974 (2005-10-01), Wischik et al.
patent: 2002/0016372 (2002-02-01), Allison
patent: 2006/0014216 (2006-01-01), Wischik et al.
patent: 0 737 671 (1996-10-01), None
patent: 8193026 (1996-07-01), None
patent: WO 93/11231 (1993-06-01), None
patent: WO 96/04915 (1996-02-01), None
patent: WO 96/30766 (1996-10-01), None
patent: WO 01/91740 (2001-12-01), None
patent: WO 02/055720 (2002-07-01), None
patent: WO 02/059150 (2002-08-01), None
patent: WO 02/075318 (2002-09-01), None
patent: WO 2005/030676 (2005-04-01), None
patent: WO 2006/032879 (2006-03-01), None
Prophylaxis. (n.d.). Merriam-Webster's Medical Dictionary. Retrieved Dec. 21, 2007, from Dictionary.com website: http://dictionary.reference.com/browse/prophylaxis.
Abstract, Thal, Prevention of Alzheimer disease, Alzheimer Disease and Associated Disorder, Jul.-Sep.:20(3 suppl 2):S97-9, 2006.
Surmeir, Calcium, ageing, neuronal vulnerability in Parkinson's disease, Lancet Neurology, 6:933-38, 2007.
Kamagai, Yoshito et al., “Inhibition of Nitric Oxide Formation by Neuronal Nitric Oxide Synthase by Quinones: Nitric Oxide Synthase as a Quinone Reductase”, XP-002217439 abstract, Chemical Research in Toxicology (1998).
Danoun, Saida et al., “Synthesis and Protozoacidal Activity of New 1,4-Naphthoquinones”, XP-002217440 abstract, Heterocyclic Communications: (1999).
Oommen, Elsie et al., “Antitumor Efficacy of Cyclodextrin-Complexed and Niosome-Encapsulated Plumbagin in Mice Bearing Melanoma B16F1”, XP-002217441 abstract, Pharmacy and Pharmacology Communications (1999).
Bhosale, S.H., et al., “Pharmacological Studies of Isomeric [sic] Juglones on the Isolated Frog Heart”, XP-002217442, Indian Journal of Pharmacology (1999).
Nishizawa Yoshinori, “Hair Growing and Restoring Agent”, Patent Abstracts of Japan, 11335244, Dec. 7, 1999.
Allison, A.C., “The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease”, XP-001117580, Medical hypothesis, vol. 57, No. 2, Aug. 2001.
Gong, C.X. et al., “Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A”, XP-000578896, Neuroscience, vol. 61, No. 4, 1994.
Ko, Li-wen, et al., “Menadione-induced tau dephosphorylation in cultured human neuroblastoma cells”, XP-001118168, Brain Research, Netherlands, Jun. 20, 1997.
U.S. Appl. No. 11/391,675, filed Mar. 29, 2006, C. M. Wischik, et al.
M. von Bergen, et al. “Assembly of tau protein into Alzheimer's paired helical filaments depends on a local sequence motif forming beta structure”, Proceedings of the National Academy of Sciences of USA, National Academy of Science, May 9, 2000, vol. 97, No. 10, pp. 5129-5134.
M. Pickhardt, et al., “Anthraquinones inhibit tau aggregation and dissolve Alzheimer paired helical filaments in vitro and in cells”, Journal of Biological Chemistry, 2005, vol. 280, pp. 3628-3635.
H. Aizawa, et al., “Microtubule-binding domain of tau proteins”, Journal of Biological Chemistry, 1988, vol. 263, pp. 7703-7707.
C.M. Wischik, F. Theuring and C.R. Harrington, “The molecular basis of tau protein pathology in Alzheimer's disease and related neurodegenerative dementias”, In Neurobiology of Alzheimer's Disease (Eds. D. Dawbarn & S.J. Allen) Oxford University Press, Oxford, pp. 103-206.
C. Wischik, “Molecular neuropathology of Alzheimer's disease”, John Libbey & Co., 1991, pp. 239-250.
R. Lai, “The Role of Abnormal Phosphorylation of Tau Protein in the Development of Neurofibrillary Pathology in Alzheimer's Disease”, pp. 1-243.
C. Wischik, “Molecular Neuropathology of Alzheimer's Disease” (1989), pp. 44-70.
Garcini et al.,Biochemical and Biophysical Research Communications, Self Assembly of Microtubule Associated Protein TAU into Filaments Resembling those found in Alzheimer Disease (1986), pp. 790-797.
Garcini et al.J. Biocehm. 102, No. 6, “In Vitro Conditions for the Self-Polymerization of the Microtubule-Associated Protein, Tau Factor” (1987), pp. 1415-1421.
Garcini et al.,Elsevier Science Publishers B.V., “Tau Factor Polymers are Similar to Paired Helical Filaments of Alzheimer's Disease” (1988), pp. 150-154.
Ksiezak-Reding and Yen,Neuron, vol. 6, pp. 717-728, Structural Stability of Paired Helical Filaments Requires Microtubule-Binding Domains of Tau: A Model for Self-Association (1991).
M. Goedert et al., “Tau Proteins of Alzheimer Paired Helical Filaments: Abnormal Phosphorylation of All Six Brain isoforms”,Neuron, vol. 8, pp. 159-168, Jan. 1992.
R. Jakes et al., “Identification of 3- and 4-repeat Tau Isoforms Within The PHF in Alzheimer's Disease”,The EMBO Journal, vol. 10, No. 10, pp. 2725-2729, 1991.
M. Novak et al., “Molecular Characterization of the Minimal Protease Resistant Tau Unit of the Alzheimer's Disease Paired Helical Filament”,The EMBO Journal, vol. 12, No. 1, pp. 365-370, 1993.
S.-H. Yen et al., “Alzheimer's Neurofibrillary Tangles Contain Unique Epitopes and Epitopes in Common With the Heat-Stable Microtubule Associated Proteins Tau and MAP2”,AJP, Jan. 1987, vol. 126, pp. 81-91.
J.P. Brion et al., “Characterization of a Partial cDNA Specific for the High Molecular Weight Microtubule-Associated Protein MAP2 That Encodes Epitopes Shared with Paired Helical Filaments of Alzheimer's Disease”,Dementia, 1990:1 pp. 304-315.
M.W. Klymkowsky, “Weaving a Tangled Web: the Interconnected Cytoskeleton”,Nature Cell Biology, vol. 1, No. 5, p. E121 (1999).
Fasulo et al., “Overexpression of Alzheimer's PHF core tau fragments: implications for the tau truncation hypothesis”, Rapid Science Publishers, Alzheimer's Research, vol. 2, No. 5, pp. 195-200, Oct. 1996.
Wille et al.,J. Cell Biol., 118 (1992) 573-584, Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro.
Ksiezak-Reding and Wall,Neurobiology of Aging, vol. 15, No. 1, pp. 11-18. “Mass and Physical Dimensions of Two Distinct Populations of Paired Helical Filaments” (1993).
Wischik et al.,Proc. Natl. Acad. Sci. USA, vol. 85, pp. 4506-4510 (1988) “Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease”.
Wischik et al.,Proc. Natl. Acad. Sci. USA, vol. 85, pp. 4884-4888, “Structural characterization of the core of the paired helical filament of Alzheimer disease” (1988).
Ksiezak-Reding, Assembled tau filaments differ from native paired helical filaments as determiend by scanning transmission electron microscopy (STEM) (1998), pp. 86-98.
Mena et al.,Journal of Neuropathology and Experimetnal Neurology, “A Progressive Depsotion of Paired Helical Filaments (PHF) in the Brain Characterizes the Evolution of Dementia in Alzheimer's Disease” (1991), pp. 474-490.
Mena et al.,Acta Neuropathol., Monitoring Pathological Assembly of tau and β-Amyloid Proteins in Alzheimer's Disease (1994), pp. 50-56.
Mena et al.,Acta Neuropathol, “Staging the Pathological Assembly of Truncated tau Protein into Paired Helical Filaments in Alzheimer's Disease” (1995), pp. 633-641.
C.M. Wischik et al. “Quantitative Analysis of Tau Protein in Paired Helical Filament Preparations: Implicati
Harrington Charles Robert
Horsley David
Rickard Janet Elizabeth
Wischik Claude Michel
Brooks Kristie L
Foley & Lardner LLP
Richter Johann R
Wista Laboratories Ltd.
LandOfFree
Napthoquinone derivatives as inhibitors of tau aggregation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Napthoquinone derivatives as inhibitors of tau aggregation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Napthoquinone derivatives as inhibitors of tau aggregation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4123620